Peptron has stated its commitment to pushing forward with joint research, new drug development, and production facility construction without delay, in apparent response to growing investor anxiety fueled by its recent stock price decline.

In a statement delivered to investors on the 13th, the company said, "We know better than anyone that what is needed now is results, not words," adding, "We will restore lost trust through results, not words." It identified its key tasks as joint research, the development of PT403, an obesity and diabetes drug candidate, and the construction of its second Osong plant.

This statement was issued in response to a recent controversy over the target material in its joint research, as well as sharp stock price fluctuations. However, no specific achievements were disclosed, such as new joint research results, technology transfer agreements, or clinical trial approvals.

◆ Stock Price Trends Peptron closed at 108,200 won on the KOSDAQ market on the 13th, down 3,400 won from the previous trading day. The decline was 3.05%, with the stock falling to as low as 104,000 won intraday to set a new 52-week low.

Earlier, after the regular market close on the 9th, the stock plunged to its lower limit in the after-hours market and again fell by the daily price limit during the regular trading session on the 10th. The widening gap between market expectations regarding joint research with a global pharmaceutical company and the company's own explanation was cited as the direct cause.

◆ Position on Joint Research The company explained that the joint research is not limited to a single specific product targeted for commercialization. It maintained that research is proceeding normally on multiple substances, including next-generation obesity and diabetes drug candidates and central nervous system disease candidates held by the global pharmaceutical company.

However, the fact that joint research is underway and the future signing of a technology transfer or commercialization agreement are separate matters. Given that the target materials and research results are not specifically disclosed due to confidentiality obligations under the contract, it is difficult for investors to objectively assess the economic value of the joint research.

◆ Future Tasks and Evaluation Criteria Peptron stated that it will more proactively communicate its disclosable research and development achievements and business progress than before. The company's policy is to provide prompt and transparent guidance on matters important to investment decisions in accordance with relevant laws and procedures.

PT403, a once-monthly, semaglutide-based obesity and diabetes drug candidate, is targeting the submission of a clinical trial plan within this year. The second Osong plant, which will serve as the commercial production base for the drug delivery platform Smart Depot, is being prepared with a target to break ground in September.

However, these are not yet completed achievements. The actual submission of the clinical trial plan for PT403 and its approval by regulatory authorities, as well as the groundbreaking and completion schedules for the second Osong plant and production facility certifications, must all be confirmed.

Restoring market confidence requires measurable outcomes rather than additional statements. Advancing to the next stage of joint research, signing follow-up agreements, entering clinical trials for PT403, and breaking ground on the second Osong plant will likely serve as the benchmarks for evaluation. Having emphasized "results, not words," the specificity of the outcomes disclosed going forward has become more important than the strength of its explanations.

[This article was written with the assistance of AI. This article is for informational purposes only for investment reference and does not recommend buying or selling any specific stock. Securities firm forecasts and the company's announced order plans are subject to change based on market prices, exchange rates, production schedules, client inspections, and actual performance. Investment decisions and any resulting responsibility lie solely with the investor.]